Huilan Ren is an associate scientist in formulation and characterization at Verve Therapeutics, with expertise in nucleic acid delivery and analytics. Previously, she worked at Intellia Therapeutics, where she was responsible for developing lipid-based delivery platforms for gene-editing therapeutics based on CRISPR/Cas9 mechanisms. Prior to Intellia, she held associate scientist positions at Novartis Institute for Biomedical Research with a focus on in-process protein analytics. She received her M.S. in pharmaceutical sciences from Northeastern University while researching lipid-based nanoparticles, micelles, and polymeric liposomes with small molecule anti-cancer drugs.